ReviewBMJ paediatrics open2026
Rheumatic heart disease in children and adolescents, part 1: epidemiology, pathogenesis and diagnosis.
Review in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic heart disease (RHD) remains a leading cause of acquired cardiovascular disease in children and adolescents globally, despite dramatic declines in high-income settings. This review synthesises contemporary evidence on the epidemiology, pathogenesis, natural history and diagnosis of rheumatic fever (RF) and RHD in young populations, with a focus on regions with high disease burden.Over recent decades, improvements in socio-economic conditions and access to healthcare have led to marked reductions in RF and RHD across much of Europe, North America and parts of Asia. In contrast, the disease persists at high prevalence in sub-Saharan Africa, South Asia, the Pacific Islands and among Indigenous and marginalised populations within high-income countries. In these settings, RF often occurs at younger ages, disease progression is accelerated and access to timely diagnosis and care is limited, resulting in substantial morbidity and premature mortality.Pathogenetic models continue to support immune-mediated valvular injury following Group A streptococcal infection, with increasing evidence that both pharyngeal and skin infections contribute to disease initiation. However, determinants of individual susceptibility and the mechanisms underlying progression from infection to chronic valvular damage remain incompletely understood. Importantly, recent observational and trial data challenge the traditional linear paradigm in which clinically apparent RF precedes RHD, demonstrating that many children develop early valvular disease without recognised RF episodes.Echocardiography has transformed the diagnosis of RHD, revealing a substantial burden of clinically silent disease and enabling earlier identification along the disease spectrum. Updated World Heart Federation echocardiographic criteria and recent WHO guidelines now support screening in high-risk populations and a staged approach to disease classification. Evidence that secondary antibiotic prophylaxis can prevent progression of early RHD reinforces the importance of early detection.Together, these advances reframe RHD as a preventable chronic disease with a detectable early phase, providing a strong foundation for effective prevention, timely diagnosis and improved outcomes in children and adolescents living in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.